Last updated: June 23, 2026
What patents are asserted in Pierre Fabre Medicament SAS v. Annora Pharma Private Limited (1:22-cv-01442)?
Direct answer: The specific asserted patent numbers, patent family(s), and asserted claims are not stated in the provided information.
Which patent holders and assignees are named
No plaintiff-side patent holder, assignee, or in-title owner information is provided beyond the suing entity name.
How many patents are in suit
No count of asserted patents is provided.
Which product(s) and NDA/ANDA/BLA are implicated
The drug name(s), application number(s) (NDA/ANDA/BLA), and Orange Book tie-ins are not included.
What is the procedural posture in 1:22-cv-01442 (motions, hearings, Markman)?
Direct answer: The pleadings, key motion practice, and any claim construction (Markman) outcomes are not provided.
Complaint and answer timeline
Filing and service dates are not provided.
Any scheduled trial dates or case management milestones
No case schedule data is provided.
Summary judgment or dismissal status
No disposition data is provided.
What is Pierre Fabre’s infringement theory in 1:22-cv-01442?
Direct answer: The infringement theory (literal infringement versus doctrine of equivalents, and which accused features or manufacturing steps) is not provided.
Direct infringement vs. induced/contributory
No allegations of inducement or contributory infringement are provided.
ANDA/Biologics pathway linkage
No FDA application linkage is provided that would let a postures-based infringement analysis be made.
How does Annora Pharma defend against the claims in 1:22-cv-01442 (invalidity, noninfringement, unenforceability)?
Direct answer: The stated defenses (invalidity grounds, §112 defenses, inequitable conduct/unenforceability, noninfringement arguments) are not provided.
Invalidity arguments typically used
No actual grounds are provided (e.g., anticipation/obviousness over specific prior art, indefiniteness, written description, enablement).
Unenforceability defenses
No inequitable conduct or similar defenses are provided.
What does the patent estate analysis show for Pierre Fabre in this litigation?
Direct answer: Without asserted patents and their expiration and claim scope, an estate-strength view cannot be constructed.
Patent expiration exposure
No expiration dates for in-suit patents are provided.
Claim-scope risk factors
No claim construction outcomes or claim charts are provided.
What regulatory context drives the dispute (Hatch-Waxman Paragraph IV, 505(b)(2), biosimilar exclusivity, 351(k))?
Direct answer: The FDA regulatory posture is not provided. That includes whether this is an ANDA Paragraph IV, an ANDA 505(b)(2) dispute, or a biologics biosimilar dispute.
Orange Book listing status
No Orange Book listing details are provided.
Exclusivity driving the suit
No 5-year/3-year exclusivity, patent term extension, or pediatric exclusivity information is provided.
Is there a settlement agreement, consent judgment, or dismissal in 1:22-cv-01442?
Direct answer: No settlement, dismissal, or consent judgment terms are included.
“Stay” or “automatic stay” mechanics
No timing details are provided to analyze automatic stay triggers.
Which court orders or filings are key in 1:22-cv-01442?
Direct answer: The key docket events (e.g., motion to dismiss, claim construction order, Daubert rulings, dispositive rulings) are not provided.
Exhibits and expert reports
No expert schedule or report content is included.
Commercial and licensing impact: what changes if Annora Pharma wins or loses?
Direct answer: The business impact depends on the accused product’s regulatory entry path, launch timing, and market exclusivity, none of which are provided.
Generic entry risk for Annora
No entry timing or approval status is provided.
Revenue exposure for Pierre Fabre
No revenue attribution or market impact is provided.
How does this case compare to other Pierre Fabre patent disputes?
Direct answer: No other disputes or comparative benchmarks are provided.
Litigation pattern and strategy
No pattern information is provided.
Key Takeaways
No complete litigation summary or infringement/validity analysis can be produced from the information provided because the asserted patent list, FDA application linkage, and docket disposition details are not included.
FAQs
- What is the filing date and current status of 1:22-cv-01442?
- Which patents does Pierre Fabre assert against Annora in 1:22-cv-01442?
- Is 1:22-cv-01442 a Paragraph IV Hatch-Waxman challenge or a biosimilar dispute?
- What claim construction rulings affect the infringement analysis in 1:22-cv-01442?
- Did the parties enter a settlement or consent judgment in this case?
References
No sources were provided in the prompt to cite.
